EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPNAG00000018238
Gene Symbol: GABBR1
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPNAG00000006149
Gene Symbol: GABBR1
3 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSPNAG00000008004
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSPNAG00000001049
Gene Symbol: LOC108444443
3 Cross references
184 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSPNAG00000026590
Gene Symbol: GLP2R
2 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSPNAG00000009302
Gene Symbol: GCGR
3 Cross references
185 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSPNAG00000010593
Gene Symbol: LOC108430977
3 Cross references
206 Possible Orthologues:

Glucokinase

Ensembl ID : ENSPNAG00000018873
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSPNAG00000018577
Gene Symbol: GBA1
3 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSPNAG00000022102
Gene Symbol: GRIN1
3 Cross references
151 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSPNAG00000014710
Gene Symbol: GRIN2A
3 Cross references
98 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSPNAG00000014329
Gene Symbol: GRIN2B
3 Cross references
261 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).